Revenue segments as reported by the company.

Grant revenue

Clinical trial revenue

Contract revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Research and development

Selling and marketing

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Longeveron

Longeveron, Inc. is a clinical stage biotechnology company. It engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers on October 9, 2014 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Longeveron reports promising Q1 results, secures funding for growth

Longeveron's Q1 2024 earnings call highlighted positive Phase I results for HLHS and cost management efforts. The company secured funding for further development and welcomed new board members. Challenges include regulatory hurdles and market competition, but opportunities lie in expanding therapeutic applications and revenue growth potential.

Longeveron reports positive Q2 results, eyes contract services expansion

Longeveron's Q2 2024 earnings call highlighted strong performance in trials and financials, with a focus on HLHS program advancement and contract services expansion. The company faces challenges in addressing analyst inquiries and maximizing its contract services business potential, but has opportunities for revenue growth and leveraging positive trial outcomes.

Longeveron reports robust revenue growth and progresses towards FDA approval

Longeveron's Q3 2024 performance reflects strong revenue growth and advancements in regulatory pathways for their product candidate, Lomecel-B, across multiple therapeutic areas.
The company's focus on cellular therapies aligns with a lucrative market potential in the U.S., but funding needs for accelerated activities and competitive challenges pose considerations for future strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Longeveron to hold conference call today at 8:00 AM EDT Longeveron to hold conference call today at 8:00 AM EDT

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results

-- Study meets one of the two analyses of primary efficacy endpoint: statistically significant dose-response in six-minute walk test (6MWT) at Day 180

Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty

MIAMI, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its second quarter 2021 financial results on Friday, August 13, 2021 before the open of US markets. Management will host a conference call on the same day at 8:00 AM.

Longeveron to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 13, 2021

Photo by Anna Shvets from Pexels Now more than ever, regenerative medicine companies like Mesoblast (NASDAQ: MESO), Celularity (NASDAQ: CELU), Athersys (NASDAQ: ATHX), and Pluristem Therapeutics (NASDAQ: PSTI) are among others that understand the importance of creating new, effective pharmaceutical critical care products for unmet needs—especially in a post-pandemic world.

Longeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS

Longeveron Inc. (NASDAQ: LGVN) is optimistic it could receive regulatory approvals in different countries for its lead regenerative medicine product Lomecel-B (cell-based therapy) after promising results from clinical trials. The company has conducted (or is conducting) Phase 1 and 2 clinical trials in Aging Frailty, Alzheimer's disease, metabolic syndrome (a substudy in the US frailty trials), acute respiratory distress syndrome (ARDS) and hypoplastic left heart syndrome (HLHS).

Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory Approval

MIAMI, June 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that two abstracts for Lomecel-B, the Company's investigational cell therapy being developed to treat aging-related life-threatening conditions, have been accepted for poster presentation at the Gerontological Society of America (GSA) 2021 Annual Scientific Meeting, being held November 10-14, 2021 in Phoenix, AZ. The full abstracts, including the dates and times of presentations, will be provided closer to the meeting once the GSA has provided these details to Longeveron. The titles of the presentations are as follows:

Longeveron Announces Two Abstracts Accepted for Presentation at the Gerontological Society of America 2021 Annual Scientific Meeting

Longeveron CEO Geoff Green presented at the Benzinga Global Small Cap Conference held on May 13-14, 2021. In addition to sharing the company's corporate outlook, Green participated in a panel entitled “Investing in Longevity Science: The New Drugs & Therapies Designed to Prolong Your Lifespan.

Longeveron, Armed with Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer's Disease, Presenting at AAIC & Headed to Phase 2 Trials

- Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer's Disease - Miami, Florida – June 24 th , 2021 - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for aging-related and chronic disease, announced today that an abstract summarizing the results of its Phase 1 trial of Lomecel-B infusion for patients with mild Alzheimer's disease has been accepted for a Developing Topics poster presentation at the 2021 Annual Alzheimer's Association International Conference, being held July 26-30, 2021 in Denver, CO and online.

Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer's Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference

MIAMI, May 25, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Ursula Ungaro will be joining its Board of Directors as of June 1, 2021.

Longeveron Announces the Appointment of Ursula Ungaro to its Board of Directors

Will Lead Business Development Activities After 14 Years as Executive Director of Maryland Stem Cell Research Fund Will Lead Business Development Activities After 14 Years as Executive Director of Maryland Stem Cell Research Fund

Longeveron Announces the Hiring of Dan Gincel, Ph.D., as Senior Vice President, Strategic Collaborations & Scientific Affairs

Longeveron's (LGVN) CEO Geoff Green on Q1 2021 Results - Earnings Call Transcript

MIAMI, May 14, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update regarding a number of ongoing clinical trials, and also reported its financial results for the first quarter ended March 31, 2021.

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results

MIAMI, May 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its first quarter 2021 financial results on Friday, May 14, 2021 before the open of US markets. Management will host a conference call on the same day at 8:30 AM.

Longeveron to Release First Quarter 2021 Financial Results and Hold Conference Call on May 14, 2021

Dr. Joshua Hare, Longeveron's Chief Science Officer, to present during this year's Longevity Session Dr. Joshua Hare, Longeveron's Chief Science Officer, to present during this year's Longevity Session

Longeveron Selected to Present at the 2021 World Stem Cell Summit

Study intended to evaluate safety, and potential immunomodulatory effect of Lomecel-B on aging-associated decline in antibody response to vaccines in vulnerable population.

Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination

Stem cell research is an arm of biotechnology that has gained a lot of momentum over recent years. Many companies are focused on developing therapies using specialized cells from within the human body which possess unique regenerative qualities to repair and restore damaged tissues and organs.

Longeveron: A High-Quality Emerging Biotech Play

The stock price of Longeveron Inc. (Nasdaq: LGVN) increased by over 25% pre-market. This is why it happened.

LGVN Stock: Over 25% Increase Pre-Market Explanation

New York, New York--(Newsfile Corp. - April 12, 2021) - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, was recently the focus of coverage by leading financial news website and publisher, SmallCapsDaily. Longeveron is swiftly becoming a leader in the biotech and regenerative medicine space, as it continues in its efforts to combat a variety of concerns and illnesses such as aging,...

SmallCapsDaily: Longeveron Inc. Emerges as a True Blue Bio-Tech Titan

The stock price of Longeveron Inc (NASDAQ: LGVN) increased by 12.54%. This is why it happened.

LGVN Stock Price Increased 12.54%: Why It Happened

Longeveron's (LGVN) CEO Geoff Green on Q4 2020 Results - Earnings Call Transcript

MIAMI, March 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today reported its financial results for the quarter and full year ended December 31, 2020 and provided a business update.

Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

MIAMI, March 26, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced it will host a conference call at 8:30 a.m. Eastern Time on Tuesday, March 30, 2021 to discuss its fiscal 2020 financial results and provide a business update.

Longeveron Schedules 2020 Fiscal Year End Business Update Conference Call

MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, CEO of Longeveron, will be presenting at the Q1 Virtual Investor Summit.

Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24

MIAMI, March 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the underwriters of its previously completed initial public offering of Class A common stock have partially exercised their over-allotment option to purchase an additional 250,000 shares. The thirty-day over-allotment option was granted in connection with the Company's initial public offering of 2,660,000 shares of Class A common stock at a public offering price of $10.00. After giving effect to the partial exercise of the over-allotment option, the total number of shares sold by Longeveron in the offering increased to 2,910,000 shares, resulting in aggregate gross proceeds of $29,100,000 prior to deducting underwriting discounts, commissions, and other offering expenses.

Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

The stock price of Longeveron Inc. (NASDAQ: LGVN) has increased by over 73% during intraday trading as of this morning. This is why it happened.

News for Longeveron Stock (LGVN)